Epidemiology, Staging, and Management of Multiple Myeloma

Medical Sciences

Prashanth Rawla¹  SandeepAnand Padala²  Vamsi Kota³  Anusha Vakiti³  GermameHailegiorgis Ajebo³  Ravindra Kolhe⁴  Alexander Barsouk⁵  Adam Barsouk⁶ 

[1] Department of Internal Medicine, Sovah Health, Martinsville, VA 24112, USA;Department of Medicine, Division of Nephrology, Hypertension and Transplant, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA;Department of Medicine, Hematology-Oncology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA;Department of Medicine, Pathology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA;Hematology-Oncology, Allegheny Health Network, Pittsburgh, PA 15212, USA;Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, PA 19107, USA;

关键词: multiple myeloma;    epidemiology;    etiology;    risk factors;    incidence;    mortality;   

DOI  :  10.3390/medsci9010003

来源: DOAJ

【 摘 要 】

Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the global proportion). Incidence has risen by 126% globally and over 40% in the US since 1990, while global mortality has risen by 94% and US mortality has fallen by 18%. The 5 year survival in the US has more than doubled over the past decades with the introduction of new targeted therapies and transplant techniques. Risk factors for MM include age (average age of diagnosis is 69), race (African Americans are over double as likely to be diagnosed), sex (men are at a 1.5× risk), and family history. Diagnosis includes serum or urine electrophoresis and free light-chain assay but requires bone marrow biopsy. It is distinguished from smoldering myeloma and monoclonal gammopathy of undetermined significance by a high (>3 g/dL) level of M-protein (monoclonal light chains) and the presence of CRAB (Hypercalcemia, Renal failure, Anemia, Bone pain) symptoms, which include hypercalcemia, renal failure, anemia, and bone pain, suggesting an end-organ damage. International staging system staging involves beta 2 microglobulin and albumin levels, while the revised system considers prognostic factors such as lactate dehydrogenase levels and chromosomal abnormalities. Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.

【 授权许可】

Unknown